bevacizumab-tnjn Vegzelma
Selected indexed studies
- Bevacizumab. (, 2006) [PMID:30000790]
- Physicochemical stability of a bevacizumab biosimilar in vials and diluted preparations: Implications for hospital practice and inventory management. (Ann Pharm Fr, 2025) [PMID:40518070]
- Assessing Protein Content and Dimer Formation in the Bevacizumab Reference Product and Biosimilar Versions Marketed in Spain. (Pharmaceutics, 2024) [PMID:39771500]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Assessing Protein Content and Dimer Formation in the Bevacizumab Reference Product and Biosimilar Versions Marketed in Spain. (2024) pubmed
- Bevacizumab. (2006) pubmed
- Physicochemical stability of a bevacizumab biosimilar in vials and diluted preparations: Implications for hospital practice and inventory management. (2025) pubmed
- Physicochemical stability of bevacizumab biosimilar CT-P16 (Vegzelma) concentrate for solution stored in original vials after first opening. (2026) pubmed